Skip to main content

Table 3 Univariate and multivariable analyses of factors predictive of overall survival

From: Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Variables Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
AbiRT     
 Yes versus no 0.15 (0.05, 0.48) 0.001 0.17 (0.05, 0.58) 0.004
Oligometastasis     
 Yes versus no 0.52 (0.30, 0.93) 0.028 0.75 (0.39, 1.44) 0.387
PSA > 20 ng/mL     
 Yes versus no 2.16 (1.23, 3.79) 0.007 1.66 (0.93, 2.96) 0.089
Prognostic index     
 Interm/poor versus favorable 3.11 (1.64, 5.92) 0.001 2.71 (1.37, 5.35) 0.004
Chemo-naïve at Abi     
 Yes versus no 0.45 (0.25, 0.81) 0.008 0.81 (0.41, 1.61) 0.548
  1. PSA prostate-specific antigen, Interm intermediate, Chemo-naïve chemotherapy-naïve upon abiraterone treatment, HR hazard ratio, CI confidential interval